Decitabine/E 7727 - Astex

Drug Profile

Decitabine/E 7727 - Astex

Alternative Names: ASTX 727; Decitabine/E7727; E-7727/decitabine

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Astex Pharmaceuticals
  • Class Antineoplastics; Aza compounds; Deoxyribonucleosides; Pyrimidine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Cytidine deaminase inhibitors; DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Myelodysplastic syndromes

Most Recent Events

  • 03 Dec 2016 Efficacy, adverse events and pharmacokinetics data from a phase I/II trial in Myelodysplastic syndromes presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
  • 25 May 2016 Phase I/II development is ongoing in USA
  • 25 May 2016 Phase-I/II clinical trials in Myelodysplastic syndromes in Canada (PO) (NCT02103478)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top